Prometheus Biosciences (RXDX) Stock Forecast, Price Target & Predictions
RXDX Stock Forecast
Prometheus Biosciences stock forecast is as follows: an average price target of $138.57 (represents a -30.69% downside from RXDX’s last price of $199.92) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
RXDX Price Target
The average price target for Prometheus Biosciences (RXDX) is $138.57 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $67.00. This represents a potential -30.69% downside from RXDX's last price of $199.92.
RXDX Analyst Ratings
According to 7 Wall Street analysts, Prometheus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RXDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Prometheus Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 16, 2023 | Annabel Samimy | Stifel Nicolaus | $200.00 | $114.01 | 75.42% | 0.04% |
| Jan 31, 2023 | - | Goldman Sachs | $144.00 | $113.66 | 26.69% | -27.97% |
| Dec 08, 2022 | Jeff Jones | Oppenheimer | $125.00 | $117.21 | 6.65% | -37.47% |
| Dec 08, 2022 | Gregory Renza | RBC Capital | $111.00 | $117.21 | -5.30% | -44.48% |
| Dec 08, 2022 | Julian Harrison | BTIG | $181.00 | $117.21 | 54.42% | -9.46% |
| Dec 08, 2022 | Tiago Fauth | Credit Suisse | $142.00 | $117.21 | 21.15% | -28.97% |
| Dec 08, 2022 | Julian Harrison | BTIG | $104.84 | $95.80 | 9.44% | -47.56% |
| Aug 28, 2022 | Yasmeen Rahimi | Piper Sandler | $67.00 | $49.40 | 35.63% | -66.49% |
| Jun 10, 2022 | Yasmeen Rahimi | Piper Sandler | $53.00 | $26.35 | 101.14% | -73.49% |
The latest Prometheus Biosciences stock forecast, released on Apr 16, 2023 by Annabel Samimy from Stifel Nicolaus, set a price target of $200.00, which represents a 75.42% increase from the stock price at the time of the forecast ($114.01), and a 0.04% increase from RXDX last price ($199.92).
Prometheus Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $199.92 | $199.92 | $199.92 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Prometheus Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Prometheus Biosciences's last price of $199.92. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 31, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Dec 08, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Dec 08, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Dec 08, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Dec 08, 2022 | BTIG | Buy | Buy | Hold |
| Oct 04, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 04, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Aug 29, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 28, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 10, 2022 | Piper Sandler | - | Overweight | Initialise |
Prometheus Biosciences's last stock rating was published by Goldman Sachs on Jan 31, 2023. The company gave RXDX a "Buy" rating, the same as its previous rate.
Prometheus Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.85 | $39.71 | 209.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| ETNB | 89bio | $8.38 | $22.00 | 162.53% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| VKTX | Viking Therapeutics | $51.63 | $102.40 | 98.33% | Buy |
| IMVT | Immunovant | $26.54 | $42.83 | 61.38% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| ROIV | Roivant Sciences | $11.82 | $16.21 | 37.14% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| KRYS | Krystal Biotech | $182.29 | $191.00 | 4.78% | Buy |
| MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
| ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |